Regeneus logo

RGS - Regeneus Share Price

A$0.06 -0.0  -13.0%

Last Trade - 21/02/20

Sector
Healthcare
Size
Micro Cap
Market Cap £7.81m
Enterprise Value £11.5m
Revenue £12.9k
Position in Universe 1274th / 1837
Bullish
Bearish
Unlock RGS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RGS Revenue Unlock RGS Revenue

Net Income

RGS Net Income Unlock RGS Revenue

Normalised EPS

RGS Normalised EPS Unlock RGS Revenue

PE Ratio Range

RGS PE Ratio Range Unlock RGS Revenue

Dividend Yield Range

RGS Dividend Yield Range Unlock RGS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RGS EPS Forecasts Unlock RGS Revenue
Profile Summary

Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated August 14, 2007
Public Since September 18, 2013
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 253,403,758
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address Ground floor 25 Bridge St, PYMBLE, 2073, Australia
Web http://www.regeneus.com.au/
Phone +61 2 94998010
Contact ()
Auditors Grant Thornton Audit Pty Ltd
RGS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RGS
Upcoming Events for RGS
Similar to RGS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.